Search Results - "Schilham, Melline M G"

Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology by Privé, Bastiaan M., Israël, Bas, Schilham, Melline G. M., Muselaers, Constantijn H. J., Zámecnik, Patrik, Mulders, Peter F. A., Witjes, J. Alfred, Sedelaar, Michiel, Mehra, Niven, Verzijlbergen, Fred, Janssen, Marcel J. R., Gotthardt, Martin, Barentsz, Jelle O., van Oort, Inge M., Nagarajah, James

“…Background PSMA-PET is a novel imaging modality for the staging of prostate cancer (PCa). While there are several PSMA ligands available, F-18-PSMA-1007 is…”
Get full text

Imaging and photodynamic therapy of prostate cancer using a theranostic PSMA-targeting ligand by Derks, Yvonne H. W., Schilham, Melline G. M., Rijpkema, Mark, Smeets, Esther M. M., Amatdjais-Groenen, Helene I. V., Kip, Annemarie, van Lith, Sanne A. M., van de Kamp, Jill, Sedelaar, J. P. Michiel, Somford, Diederik M., Simons, Michiel, Laverman, Peter, Gotthardt, Martin, Löwik, Dennis W. P. M., Heskamp, Sandra, Lütje, Susanne

“…Purpose Incomplete resection of prostate cancer (PCa) results in increased risk of disease recurrence. Combined fluorescence-guided surgery with tumor-targeted…”
Get full text

Prostate-Specific Membrane Antigen-Targeted Radioguided Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients with a Suspicion of Locoregional Lymph Node Metastases: The DETECT Trial by Schilham, Melline G M, Somford, Diederik M, Küsters-Vandevelde, Heidi V N, Hermsen, Rick, van Basten, Jean Paul A, Hoekstra, Robert J, Scheenen, Tom W J, Gotthardt, Martin, Sedelaar, J P Michiel, Rijpkema, Mark

“…Prostate-specific membrane antigen (PSMA)-targeted radioguided surgery (RGS) aims to optimize the peroperative detection and removal of PSMA-avid lymph node…”
Get full text

Comparison of risk-calculator and MRI and consecutive pathways as upfront stratification for prostate biopsy by Reesink, Daan J., Schilham, Melline G. M., van der Hoeven, Erik J. R. J., Schoots, Ivo G., van Melick, Harm H. E., van den Bergh, Roderick C. N.

“…Purpose In biopsy naïve men suspected for prostate cancer (PCa), it is uncertain how a risk-calculator and bi-parametric (bp) MRI should be combined to decide…”
Get full text

Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study by Privé, Bastiaan M, Peters, Steffie M B, Muselaers, Constantijn H J, van Oort, Inge M, Janssen, Marcel J R, Sedelaar, J P Michiel, Konijnenberg, Mark W, Zámecnik, Patrik, Uijen, Maike J M, Schilham, Melline G M, Eek, Annemarie, Scheenen, Tom W J, Verzijlbergen, J Fred, Gerritsen, Winald R, Mehra, Niven, Kerkmeijer, Linda G W, Smeenk, Robert J, Somford, Diederik M, van Basten, Jean-Paul A, Heskamp, Sandra, Barentsz, Jelle O, Gotthardt, Martin, Witjes, J Alfred, Nagarajah, James

“…[ Lu]Lu-PSMA-617 radioligand therapy ( Lu-PSMA) is a novel treatment for metastatic castration-resistant prostate cancer (mCRPC), which could also be applied…”
Get full text

How Advanced Imaging Will Guide Therapeutic Strategies for Patients with Newly Diagnosed Prostate Cancer in the Years to Come by Schilham, Melline G.M., Rijpkema, Mark, Scheenen, Tom, Hermsen, Rick, Barentsz, Jelle O., Michiel Sedelaar, J.P., Kusters-Vandevelde, Heidi, Kerkmeijer, Linda G.W., Somford, Diederik M., Gotthardt, Martin

“…In recent years, clinical use of novel advanced imaging modalities in prostate cancer detection, staging, and therapy has intensified and is currently…”
Get full text

Head-to-Head Comparison of 68Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10–Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients by Schilham, Melline GM, Zamecnik, Patrik, Privé, Bastiaan M, Israël, Bas, Rijpkema, Mark, Scheenen, Tom, Barentsz, Jelle O, Nagarajah, James, Gotthardt, Martin

“…Accurate assessment of lymph node (LN) metastases in prostate cancer (PCa) patients is critical for prognosis and patient management. Both prostate-specific…”
Get full text

An Update to the Pilot Study of 177Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer by Privé, Bastiaan M., Muselaers, Constantijn H. J., van Oort, Inge M., Janssen, Marcel J. R., Peters, Steffie M. B., van Gemert, Willemijn A. M., Uijen, Maike J. M., Schilham, Melline M. G., Sedelaar, J. P. Michiel, Westdorp, Harm, Mehra, Niven, Gotthardt, Martin, Barentsz, Jelle O., Gerritsen, Winald R., Witjes, J. Alfred, Nagarajah, James

“…177 Lu-PSMA-617 radioligand therapy is a novel treatment for end-stage prostate cancer, which could also be applied to patients with hormone-sensitive prostate…”
Get full text

Reply to Francesco Montorsi, Simone Scuderi, Alberto Briganti, and Giorgio Gandaglia’s Letter to the Editor re: Melline G.M. Schilham, Mark Rijpkema, Tom Scheenen, et al. How Advanced Imaging Will Guide Therapeutic Strategies for Patients with Newly Diagnosed Prostate Cancer in the Years to Come. Eur Urol 2022;82:578–80 by Schilham, Melline G.M., Rijpkema, Mark, Scheenen, Tom, Hermsen, Rick, Barentsz, Jelle O., Sedelaar, J.P.Michiel, Kusters-Vandevelde, Heidi, Kerkmeijer, Linda G.W., Somford, Diederik M., Gotthardt, Martin

Get full text

Head-to-Head Comparison of 68 Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10-Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients by Schilham, Melline G M, Zamecnik, Patrik, Privé, Bastiaan M, Israël, Bas, Rijpkema, Mark, Scheenen, Tom, Barentsz, Jelle O, Nagarajah, James, Gotthardt, Martin

“…Accurate assessment of lymph node (LN) metastases in prostate cancer (PCa) patients is critical for prognosis and patient management. Both prostate-specific…”
Get full text

How Image-Guided Pathology Can Improve the Detection of Lymph Node Metastases in Prostate Cancer by Schilham, Melline G.M., Küsters-Vandevelde, Heidi, Somford, Diederik M., Rijpkema, M., Gotthardt, Martin

“…Detection of lymph node (LN) metastases in prostate cancer (PCa) is pivotal for accurate staging and determining treatment options. To date, the reference…”
Get full text

An Update to the Pilot Study of 177 Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer by Privé, Bastiaan M, Muselaers, Constantijn H J, van Oort, Inge M, Janssen, Marcel J R, Peters, Steffie M B, van Gemert, Willemijn A M, Uijen, Maike J M, Schilham, Melline M G, Sedelaar, J P Michiel, Westdorp, Harm, Mehra, Niven, Gotthardt, Martin, Barentsz, Jelle O, Gerritsen, Winald R, Witjes, J Alfred, Nagarajah, James

“…Lu-PSMA-617 radioligand therapy is a novel treatment for end-stage prostate cancer, which could also be applied to patients with hormone-sensitive prostate…”
Get full text